816PAndrogen decline and outcome in castration resistant prostate cancer (mCRPC) patients treated with docetaxel (Doc), prednisone +/- bevacizumab (B). (23rd October 2018) - Ryan, C J; Dutta, S; Kelly, W; Morris, M J; Taplin, M-E; Halabi, S